0HX7.L
Adicet Bio, Inc. [0HX7.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0HX7.L Stock Summary
Top 10 Correlated ETFs
0HX7.L
Top 10 Correlated Stocks
0HX7.L
In the News
0HX7.L Financial details
Company Rating
-
Market Cap
184.38M
Income
-142.66M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
143
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-1.12
Forward P/E
-
PEG
-0.12
P/S
-
P/B
0.83
P/C
-
P/FCF
-1.15
Quick Ratio
9.27
Current Ratio
9.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.32
EPS next Y
-
EPS next Q
-
EPS this Y
94.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-24.11%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-40.52%
-
-
-
-
SMA20
-27.71%
SMA50
-35.48%
SMA100
-46.9%
Inst Own
-
Inst Trans
-
ROA
-61%
ROE
-58%
ROC
-0.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.102-7.6
52W High
-91.17%
52W Low
-38.18%
RSI
43.12
Rel Volume
-
Avg Volume
6.36K
Volume
30
Perf Week
13.08%
Perf Month
-18.71%
Perf Quarter
-
Perf Half Y
-56.77%
-
-
-
-
Beta
1.624
-
-
Volatility
0.01%, 0.12%
Prev Close
-1.1%
Price
0.6182
Change
-1.89%
Company Profile
- Volume Average 6.36K
- Market Capitalization 184.38M
- Employee 143
- CEO Mr. Chen Schor BA, CPA, M.B.A.
- Headquarters Boston,MA,US
- IPO Date 2021-01-08
-
Website
https://www.adicetbio.com 
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
